SCHEMBL18072931

SCHEMBL18072931

Cc1cc(-c2ccc([N+](=O)[O-])cc2)nc(-c2ccco2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MYC P01106 2/20 0.66
▸ MAX P61244 1/20 0.66
▸ ALDH1A1 P00352 4/20 0.48
▸ MAPT P10636 4/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ PDE4A P27815 1/20 0.47
▸ PDE4D Q08499 1/20 0.47
▸ CHEK1 O14757 1/20 0.46
▸ LIMK1 P53667 1/20 0.46
▸ CDK5 Q00535 1/20 0.46
▸ CLK4 Q9HAZ1 1/20 0.46
▸ RAD51 Q06609 1/20 0.46
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ LMNA P02545 2/20 0.44
▸ GAA P10253 2/20 0.44
▸ CYP1A2 P05177 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17934451 0.91 MYC (0.72) MYCMAXALDH1A1MAPTSMN1; SMN2
SCHEMBL18070703 0.86 MYC (0.62) MYCMAXALDH1A1MAPTSMN1; SMN2
SCHEMBL17927376 0.84 MYC (0.76) MYCMAXALDH1A1MAPTPDE4A
SCHEMBL17927411 0.84 MYC (0.72) MYCMAXALDH1A1MAPTSMN1; SMN2
SCHEMBL16810362 0.81 MYC (0.82) MYCMAXMAPTPDE4APDE4D
SCHEMBL17927298 0.81 MYC (0.71) MYCMAXALDH1A1MAPTSMN1; SMN2
SCHEMBL16810386 0.81 MYC (0.72) MYCMAXALDH1A1MAPTSMN1; SMN2
SCHEMBL17927341 0.81 MYC (0.70) MYCMAXALDH1A1MAPTMEN1
SCHEMBL17927346 0.81 MYC (0.70) MYCMAXALDH1A1MAPTMEN1
SCHEMBL16792502 0.80 MYC (1.00) MYCMAXALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264560-A1 SMALL MOLECULE C-MYC INHIBITORS SORRENTO THERAPEUTICS, INC. 2016-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264560-A1 SMALL MOLECULE C-MYC INHIBITORS MYC, MYCBP, MYCBP2 MYC 1/4885MAX 42/4885ALDH1A1 3976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback